摘要
自身免疫性大疱病(autoimmune blistering diseases,AIBD)是一组由自身抗体介导的皮肤黏膜水疱性疾病,传统治疗以糖皮质激素和免疫抑制剂为主。近年来,JAK抑制剂因其靶向调控JAK-STAT信号通路、阻断炎症和免疫反应的特性,成为新兴研究方向。本文综述了JAK-STAT通路在AIBD发病机制中的作用,重点探讨了芦可替尼、托法替布、乌帕替尼等JAK抑制剂在治疗天疱疮、类天疱疮中的临床应用。
Autoimmune blistering diseases(AIBD)are a group of autoimmune antibody-mediated blistering disorders affecting the skin and mucous membranes.Traditional treatments mainly rely on glucocorticoids and immunosuppressants.In recent years,JAK inhibitors have emerged as a promising research direction due to their properties of targeting and regulating the JAK-STAT signaling pathway,as well as blocking inflammatory and immune responses.The role of the JAK-STAT pathway in the pathogenesis of AIBD are reviewed in this paper,with a focus on the clinical applications of JAK inhibitors such as ruxolitinib,tofacitinib,and upadacitinib in the treatment of pemphigus and pemphigoid.
作者
仝海男
郭建辉
TONG Hainan;GUO Jianhui(Department of Traditional Chinese Medicine and Surgery,Hebei University of Traditional Chinese Medicine,Shijiazhuang 050001,China;Department of Dermatology,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Cangzhou 061001,China)
出处
《中国麻风皮肤病杂志》
2025年第9期697-702,共6页
China Journal of Leprosy and Skin Diseases
